vedolizumab
takeda
['vedolizumab', ' vedo', 'ibd']
interesting data on the use of vedolizumab in patients with #ibd and #psc from among 108 pts, 77% clinical response and 58% endoscopic response at 12 months. #acg2022 
Assistant Professor, Associate Program Director, GI & Hepatology Fellowship @UNCGastro | Research & Clinical interest in #IBD, #pouchitis, outcomes after #IPAA